This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.
Pathway / Mechanism Diagram
graph TD
A["APOE Gene"] --> B["APOE e2 (Protective)"]
A --> C["APOE e3 (Neutral)"]
A --> D["APOE e4 (Risk Factor)"]
D --> E["Impaired Abeta Clearance"]
D --> F["Enhanced Tau Phosphorylation"]
D --> G["BBB Dysfunction"]
D --> H["Reduced Lipid Transport"]
E --> I["Amyloid Accumulation"]
F --> J["Tangle Formation"]
G --> K["Neuroinflammation"]
H --> L["Impaired Synaptic Repair"]
I --> M["Neurodegeneration"]
J --> M
K --> M
L --> M
B --> N["Enhanced Abeta Clearance"]
N --> O["Reduced AD Risk"]
style D fill:#ef5350,color:#e0e0e0
style B fill:#1b5e20,color:#e0e0e0
style M fill:#ef5350,color:#e0e0e0
Research Question
AD Gap #17: How does ApoE4 confer risk at the cellular level?
What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?
Hypothesis
...
Overview
This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Research Question
AD Gap #17: How does ApoE4 confer risk at the cellular level?
What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?
Hypothesis
ApoE4 promotes AD pathogenesis through multiple mechanisms: enhanced Aβ binding and aggregation seeding, impaired Aβ clearance across the BBB, gain of neurotoxic lipoproteins, and amplified neuroinflammation via microglial dysregulation. Targeting these mechanisms will reduce AD risk in ApoE4 carriers.
Experimental Design
Model System
In vitro: Astrocyte and neuron cultures from ApoE4-TR and ApoE3-TR iPSC lines